New Cytomegalovirus Antiviral Shows Efficacy in Phase 3 Clinical Trial
JUN 22, 2017 | CONTAGION® EDITORIAL STAFF
Genovefa Papanicolaou, MD, Attending Physician, Infectious Diseases, Memorial Sloan Kettering Cancer Center, discusses a new antiviral in development to prevent cytomegalovirus.
Interview Transcript (slightly modified for readability)
“With current management strategies, we are able to control [cytomegalovirus] CMV, and prevent CMV [from] going into various organs and causing disease. However, the current antivirals have certain limitations; they can cause marrow toxicity, particularly lower the white count, or the alternative medication that we have, foscarnet, may cause kidney damage.
There is a new antiviral in development, letermovir, that was shown to be efficacious in preventing CMV in a phase 3 trial. In that study, patients were randomized to get letermovir or placebo for 14 weeks, and then we looked at the rates of CMV reactivation at 24 weeks, and patients that got letermovir had significantly less CMV reactivation at 24 weeks. This is a very exciting development because this is the first antiviral shown to be effective for CMV prevention in a phase 3 clinical trial. Letermovir was particularly safe in the phase 3 trial; it didn’t cause any marrow toxicity; it didn’t cause any nephrotoxicity. So, it appears to be very safe to be given up to 14 weeks in this very sick patient population.” DISCLOSURES: Genofeva Papanicolaou has received research funding from Merck and consultant and research funding from Astellas and Chimerix.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512